Nutritional Status Indicators as a Predictor of Achieving Remission at Week 14 during Vedolizumab Therapy in Patients with Ulcerative Colitis: A Pilot Study
Nutrients · 2023
DOI: 10.3390/nu15010240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Aleksandra Sobolewska-Włodarczyk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Medical University of Lodz, Pomorska Str. 251, 90-213 Lodz, Poland. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: statutory funds from the Medical University of Lodz, Poland.
Themen: Mangelernährung
Abstract (Originalsprache)
Background
The loss of response or failure to achieve remission to vedolizumab in ulcerative colitis (UC) patients is currently a major clinical problem. Recently, Nutritional Risk Index (NRI), Controlling Nutritional Status (CONUT), and Malnutrition Universal Screening Tool (MUST) have been suggested as a new prognostic factor of UC activity. Here, we aimed at confirmation of hypotezis that NRI, CONUT and MUST may be used as inexpensive and efficient predictive biomarkers of response in UC patients treated with vedolizumab.
Methods
This study was conducted in retrospective manner in 32 adult patients with UC of Caucasian origin (21 men and 11 women), who were qualified for 52-week therapy with vedolizumab and finished the 14-weeks from January 2020 to March 2022. Our study analyzed the 45 courses of vedolizumab therapy. Nutritional status indicators, i.e., the NRI, CONUT and MUST of each UC patient, were marked at the time of qualifying for biological treatment.
Results
In our study, the MUST score was significantly lower in UC patients who positively achieved clinical remission at week 14 during vedolizumab induction therapy (0.33 ± 0.49 vs. 1.37 ± 0.83; p = 0.002). The analysis showed the lower baseline NRI and CONUT scores in patients with positive clinical remission at week 14 (NRI: 96.42 ± 4.29 vs. 101.41 ± 7.09; p = 0.024; CONUT: 1.00 ± 1.08 vs. 2.16 ± 1.46; p = 0.031).
Conclusions
Nutritional status indicators (NRI, MUST and CONUT) may become valuable predictor of achieving remission at week 14 during vedolizumab therapy in UC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Medical University of Lodz, Pomorska Str. 251, 90-213 Lodz, Poland.
- Department of General and Oncological Surgery, Medical University of Lodz, Pomorska Str. 251, 90-213 Lodz, Poland.
ORCID-Profile: Ewa Walecka-Kapica, Marcin Włodarczyk
Förderung
- statutory funds from the Medical University of Lodz, Poland
Zitieren
APA
Sobolewska-Włodarczyk, A., Walecka-Kapica, E., Włodarczyk, M., & Gąsiorowska, A. (2023). Nutritional Status Indicators as a Predictor of Achieving Remission at Week 14 during Vedolizumab Therapy in Patients with Ulcerative Colitis: A Pilot Study. Nutrients. https://doi.org/10.3390/nu15010240
Vancouver
Sobolewska-Włodarczyk A, Walecka-Kapica E, Włodarczyk M, Gąsiorowska A. Nutritional Status Indicators as a Predictor of Achieving Remission at Week 14 during Vedolizumab Therapy in Patients with Ulcerative Colitis: A Pilot Study. Nutrients. 2023. doi:10.3390/nu15010240
BibTeX
@article{SobolewskaWodarczyk2023,
author = {Sobolewska-Włodarczyk, Aleksandra and Walecka-Kapica, Ewa and Włodarczyk, Marcin and Gąsiorowska, Anita},
title = {Nutritional Status Indicators as a Predictor of Achieving Remission at Week 14 during Vedolizumab Therapy in Patients with Ulcerative Colitis: A Pilot Study},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15010240}
}
EUVIMED